These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 28489072)

  • 1. Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration.
    Shin SM; Choi DK; Jung K; Bae J; Kim JS; Park SW; Song KH; Kim YS
    Nat Commun; 2017 May; 8():15090. PubMed ID: 28489072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct targeting of oncogenic RAS mutants with a tumor-specific cytosol-penetrating antibody inhibits RAS mutant-driven tumor growth.
    Shin SM; Kim JS; Park SW; Jun SY; Kweon HJ; Choi DK; Lee D; Cho YB; Kim YS
    Sci Adv; 2020 Jan; 6(3):eaay2174. PubMed ID: 31998840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wild-type H- and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response.
    Grabocka E; Pylayeva-Gupta Y; Jones MJ; Lubkov V; Yemanaberhan E; Taylor L; Jeng HH; Bar-Sagi D
    Cancer Cell; 2014 Feb; 25(2):243-56. PubMed ID: 24525237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective and noncovalent targeting of RAS mutants for inhibition and degradation.
    Teng KW; Tsai ST; Hattori T; Fedele C; Koide A; Yang C; Hou X; Zhang Y; Neel BG; O'Bryan JP; Koide S
    Nat Commun; 2021 May; 12(1):2656. PubMed ID: 33976200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumours.
    Yurugi H; Marini F; Weber C; David K; Zhao Q; Binder H; Désaubry L; Rajalingam K
    Oncogene; 2017 Aug; 36(33):4778-4789. PubMed ID: 28414306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of liver oncogenic potential among human RAS isoforms.
    Chung SI; Moon H; Ju HL; Kim DY; Cho KJ; Ribback S; Dombrowski F; Calvisi DF; Ro SW
    Oncotarget; 2016 Feb; 7(6):7354-66. PubMed ID: 26799184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The K-Ras, N-Ras, and H-Ras Isoforms: Unique Conformational Preferences and Implications for Targeting Oncogenic Mutants.
    Parker JA; Mattos C
    Cold Spring Harb Perspect Med; 2018 Aug; 8(8):. PubMed ID: 29038336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced HRAS G12V-Driven Tumorigenesis of Cell Lines Expressing KRAS C118S.
    Huang L; Counter CM
    PLoS One; 2015; 10(4):e0123918. PubMed ID: 25902334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of RAS: proven and potential vulnerabilities.
    Zuberi M; Khan I; O'Bryan JP
    Biochem Soc Trans; 2020 Oct; 48(5):1831-1841. PubMed ID: 32869838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A distinct class of dominant negative Ras mutants: cytosolic GTP-bound Ras effector domain mutants that inhibit Ras signaling and transformation and enhance cell adhesion.
    Fiordalisi JJ; Holly SP; Johnson RL; Parise LV; Cox AD
    J Biol Chem; 2002 Mar; 277(13):10813-23. PubMed ID: 11799108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ras inhibitors display an anti-metastatic effect by downregulation of lysyl oxidase through inhibition of the Ras-PI3K-Akt-HIF-1α pathway.
    Yoshikawa Y; Takano O; Kato I; Takahashi Y; Shima F; Kataoka T
    Cancer Lett; 2017 Dec; 410():82-91. PubMed ID: 28951129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving Prospects for Targeting RAS.
    Singh H; Longo DL; Chabner BA
    J Clin Oncol; 2015 Nov; 33(31):3650-9. PubMed ID: 26371146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogenic RAS simultaneously protects against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR signaling blockade.
    Kasper S; Breitenbuecher F; Reis H; Brandau S; Worm K; Köhler J; Paul A; Trarbach T; Schmid KW; Schuler M
    Oncogene; 2013 Jun; 32(23):2873-81. PubMed ID: 22797062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection and Quantitation of Endogenous Membrane-Bound RAS Proteins and KRAS Mutants in Cancer Cell Lines Using 1D-SDS-PAGE LC-MS
    Kaczmarczyk JA; Whiteley GR; Blonder J
    Methods Mol Biol; 2024; 2823():269-289. PubMed ID: 39052226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calmodulin and IQGAP1 activation of PI3Kα and Akt in KRAS, HRAS and NRAS-driven cancers.
    Nussinov R; Zhang M; Tsai CJ; Jang H
    Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2304-2314. PubMed ID: 29097261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ASPP2 Is a Novel Pan-Ras Nanocluster Scaffold.
    Posada IM; Serulla M; Zhou Y; Oetken-Lindholm C; Abankwa D; Lectez B
    PLoS One; 2016; 11(7):e0159677. PubMed ID: 27437940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Nrf2 on tumour growth and drug sensitivity in oncogenic K-ras-transformed cells in vitro and in vivo.
    Shao J; Glorieux C; Liao J; Chen P; Lu W; Liang Z; Wen S; Hu Y; Huang P
    Free Radic Res; 2018 Jun; 52(6):661-671. PubMed ID: 29621903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The spatiotemporal regulation of RAS signalling.
    Herrero A; Matallanas D; Kolch W
    Biochem Soc Trans; 2016 Oct; 44(5):1517-1522. PubMed ID: 27911734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Signal transduction elements of TC21, an oncogenic member of the R-Ras subfamily of GTP-binding proteins.
    Movilla N; Crespo P; Bustelo XR
    Oncogene; 1999 Oct; 18(43):5860-9. PubMed ID: 10557073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour prevention by a single antibody domain targeting the interaction of signal transduction proteins with RAS.
    Tanaka T; Williams RL; Rabbitts TH
    EMBO J; 2007 Jul; 26(13):3250-9. PubMed ID: 17568777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.